03546nas a2200469 4500008004100000022001400041245015800055210006900213260001300282300001200295490000800307520208900315653001202404653002602416653002202442653003002464653001602494653001102510653002702521653001402548653003602562653001302598653002902611653002502640653000902665653002202674653002602696653002602722100002002748700002402768700002502792700001802817700002102835700001902856700002602875700002102901700002002922700002802942700002202970700002502992856005903017 2002 eng d a0033-841900aPercutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model.0 aPercutaneous tumor ablation increased necrosis with combined rad c2002 Mar a797-8040 v2223 a

PURPOSE: To determine whether a combination of intravenous liposomal doxorubicin and radio-frequency (RF) ablation increases tumor destruction compared with RF alone in an animal tumor model.

MATERIALS AND METHODS: R3230 mammary adenocarcinoma 1.4-1.8-cm- diameter nodules were implanted subcutaneously in 132 female Fischer rats. Initially, tumors were treated with (a) conventional, monopolar RF (mean, 250 mA +/- 25 [SD] at 70 degrees C +/- 1 for 5 minutes) ablation alone, (b) RF ablation followed by intravenous administration of 1 mg of liposomal doxorubicin, (c) RF ablation followed by intravenous administration of 1 mg of empty liposomes, (d) RF ablation and direct intratumoral administration of liposomal doxorubicin, or (e) no treatment. Subsequently, the dose (0.06-2.00 mg) of liposomal doxorubicin, the timing of administration (3 days before to 3 days after RF ablation), and the time of pathologic examination (0-72 hours after treatment) were varied.

RESULTS: Mean coagulation diameter for treated tumors follows: 6.7 mm +/- 0.6, RF ablation alone; 11.1 mm +/- 1.5, RF ablation and intravenous administration of empty liposomes (P <.05, compared with RF ablation alone); and 8.4 mm +/- 1.1, RF ablation with intratumoral administration of liposomal doxorubicin (P <.05, compared with RF ablation alone). Maximal increased mean coagulation diameter (13.1 mm +/- 1.5) was observed with a combination of liposomal doxorubicin and RF ablation (P <.001, for all comparisons). The increased coagulation for combination therapy developed over 48 hours after therapy. Coagulation diameter did not vary with the doxorubicin concentration range and was not dependent on the timing of administration of liposomal doxorubicin from 3 days before to 24 hours after RF ablation.

CONCLUSION: Intravenous administration of liposomal doxorubicin can improve RF ablation, since it increases coagulation diameter in solid tumors compared with RF ablation alone or a combination of RF ablation with administration of empty liposomes.

10aAnimals10aAntineoplastic Agents10aCatheter Ablation10aCombined Modality Therapy10aDoxorubicin10aFemale10aInfusions, Intravenous10aLiposomes10aMammary Neoplasms, Experimental10aNecrosis10aNeoplasm Transplantation10aPolyethylene Glycols10aRats10aRats, Inbred F34410aSurface-Active Agents10aTumor Cells, Cultured1 aGoldberg, Nahum1 aGirnan, Geoffrey, D1 aLukyanov, Anatoly, N1 aAhmed, Muneeb1 aMonsky, Wayne, L1 aGazelle, Scott1 aHuertas, Juan, Carlos1 aStuart, Keith, E1 aJacobs, Timothy1 aTorchillin, Vladimir, P1 aHalpern, Elkan, F1 aKruskal, Jonathan, B uhttps://www.microfluidicsciences.com/drupal/?q=node/29